← Back to Search

Senolytic Drug

Fisetin for Coronavirus

Phase 2
Waitlist Available
Led By James L Kirkland, MD, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 - 59 years WITH at least one of the following comorbidities: BMI greater than or equal to 35, Diabetes, Asthma/ Chronic Obstructive Pulmonary Disease (COPD), Previous Myocardial Infarction, Previous Stroke/ Cerebrovascular Accident (CVA), Hypertension/ Atherosclerosis/ Peripheral Vascular Disease, Smoking and/or vaping, Other conditions associated with senescent cell accumulation (i.e. previous chemotherapy or radiation), SpO2 greater than or equal to 85% (on room air or less than or equal to 2 L of supplemental oxygen), Willing and able to provide written informed consent or have a legally authorized representative (LAR) who will provide informed consent, SARS-CoV-2 infection confirmed by PCR test at Mayo Clinic (or other CLIA certified) laboratory within 10 days prior to randomization.
Men or women 60 years of age or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will test whether Fisetin can help prevent the progression of coronavirus and its complications.

Who is the study for?
Adults aged 18+ with COVID-19 confirmed by a PCR test, especially those over 60 or aged 18-59 with conditions like obesity, diabetes, lung diseases (asthma/COPD), heart issues (past strokes or heart attacks), high blood pressure, history of smoking/vaping, or past chemotherapy/radiation. Must not be pregnant and willing to use contraception.Check my eligibility
What is being tested?
The trial is testing Fisetin—a drug that might reduce inflammation and prevent worsening of coronavirus symptoms—against a placebo. Participants will randomly receive either Fisetin or an inactive substance to compare outcomes.See study design
What are the potential side effects?
Specific side effects for Fisetin are not detailed here but may include typical drug reactions such as allergic responses, gastrointestinal discomforts, headaches, dizziness or other common medication-related side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 60 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in oxygenation status
Serious Adverse Events
Secondary outcome measures
CoV Severity Category

Side effects data

From 2022 Phase 2 trial • 55 Patients • NCT04771611
7%
Rash
7%
Chest pain
7%
Diarrhea
7%
Sinusitis
7%
Infectious Rash
7%
Back Pain
7%
Headache
7%
Worsening Headache
7%
Dyspnea
7%
sore throat
7%
hyperhidrosis
3%
tachycardia
3%
shortness of breath
3%
ageusia
3%
amnesia
3%
change in smell
3%
ear pain, left
3%
vomiting
3%
edema, hand, bilateral
3%
fatigue
3%
flu like symptoms
3%
Otitis media
3%
Upper Respiratory Infection
3%
Anosmia
3%
Colic Renal
3%
Nephrolithiasis Calcium Oxalate
3%
Epistaxis
3%
cough
3%
rhinitis
3%
sneezing
3%
thrush
3%
right shoulder arthroscopy, rotator cuff, repair
3%
asthma with exacerbation
3%
watering eyes (epiphora)
3%
flatulence
3%
conjunctivitis
3%
migraine
3%
bacterial vaginosis
3%
arthoplasty
3%
vertigo
3%
Systolic murmur
3%
hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment Group
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment GroupExperimental Treatment1 Intervention
Subjects will receive treatment drug Fisetin
Group II: Placebo GroupPlacebo Group1 Intervention
Subjects will receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fisetin
2016
Completed Phase 2
~200

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,176 Previous Clinical Trials
3,757,971 Total Patients Enrolled
James L Kirkland, MD, PhDPrincipal InvestigatorMayo Clinic
4 Previous Clinical Trials
285 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the maximum capacity of participants in this research endeavor?

"At present, this clinical trial is not accepting new patients. Initially posted on August 3rd 2020 and most recently edited January 17th 2022, an individual seeking to take part in a medical study may consider one of the 1011 trials recruiting participants with covid-19 or 6 studies involving Fisetin that are currently enrolling volunteers."

Answered by AI

Has Fisetin previously been tested in any other research studies?

"Currently, 6 clinical trials are being conducted on Fisetin yet none have advanced to Phase 3. The medical research is primarily based in Vail, Colorado with a handful of other locations participating in the testing."

Answered by AI

Has Fisetin obtained clearance from the US Food and Drug Administration?

"From the data available, Fisetin has been assigned a safety rating of 2 on our 1 to 3 scale. This is due to Phase 2 trial results which demonstrate some evidence supporting its security but no efficacy information."

Answered by AI

Is it currently feasible to enroll in this scientific experiment?

"This trial is no longer recruiting. It was originally posted on August 3rd 2020 and last updated on January 17th 2022. However, if you are looking for alternative studies to participate in, there are 1011 trials accepting participants with covid-19 as well as 6 clinical trials that require candidates for Fisetin testing."

Answered by AI
~13 spots leftby Dec 2024